Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Operating Income (2021 - 2025)

PAVmed has reported Operating Income over the past 5 years, most recently at -$6.8 million for Q4 2025.

  • Quarterly results put Operating Income at -$6.8 million for Q4 2025, down 31.15% from a year ago — trailing twelve months through Dec 2025 was -$21.8 million (up 55.76% YoY), and the annual figure for FY2025 was -$21.8 million, up 50.98%.
  • Operating Income for Q4 2025 was -$6.8 million at PAVmed, down from -$4.8 million in the prior quarter.
  • Over the last five years, Operating Income for PAVM hit a ceiling of -$4.7 million in Q2 2025 and a floor of -$24.6 million in Q4 2022.
  • Median Operating Income over the past 5 years was -$14.0 million (2024), compared with a mean of -$14.2 million.
  • Biggest five-year swings in Operating Income: tumbled 143.1% in 2022 and later skyrocketed 68.34% in 2024.
  • PAVmed's Operating Income stood at -$19.7 million in 2021, then fell by 25.01% to -$24.6 million in 2022, then skyrocketed by 33.41% to -$16.4 million in 2023, then skyrocketed by 68.34% to -$5.2 million in 2024, then crashed by 31.15% to -$6.8 million in 2025.
  • The last three reported values for Operating Income were -$6.8 million (Q4 2025), -$4.8 million (Q3 2025), and -$4.7 million (Q2 2025) per Business Quant data.